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Molecular alterations in malignant tumors can cause phenotypic changes in tumor cells and their 42 
microenvironment. Routine histopathology tissue slides – which are ubiquitously available for 43 
patients with solid tumors – can reflect such morphological changes. Here, we show that deep 44 
learning can consistently infer a wide range of genetic mutations, molecular tumor subtypes, 45 
gene expression signatures and standard pathology biomarkers directly from routine histology 46 
images of cancer. We developed, systematically optimized, validated and publicly released a one-47 
stop-shop workflow and applied it to routine tissue slides of more than 5000 patients across a 48 
broad spectrum of common solid tumors including lung, colorectal, breast and gastric cancer. 49 
Our findings show that a single deep learning algorithm can be trained to predict a wide range of 50 
molecular alterations from routine, paraffin-embedded histology slides stained with hematoxylin 51 
and eosin. These predictions generalize to other populations and yield spatially resolved predic-52 
tions. Our method can be implemented on mobile hardware, potentially enabling point-of-care 53 
diagnostics for personalized cancer treatment. More generally, this approach can be used to elu-54 





Precision treatment of cancer relies on detection of genetic alterations which are diagnosed by 57 
molecular biology assays.1 These tests can be a bottleneck in oncology workflows because of high 58 
turnaround time, tissue usage and costs.2 Clinical guidelines recommend molecular testing of 59 
tumor tissue for most patients with advanced solid tumors. However, in most tumor types, rou-60 
tine testing includes only a handful of alterations, such as KRAS, NRAS, BRAF mutations and mi-61 
crosatellite instability (MSI) in colorectal cancer.3 While new studies identify more and more mo-62 
lecular features of potential clinical relevance, current diagnostic workflows are not designed to 63 
incorporate an exponentially rising load of tests. For example, in colorectal cancer, previous stud-64 
ies have identified consensus molecular subtypes (CMS)4 as a candidate biomarker, but sequenc-65 
ing costs and method complexity preclude widespread testing in clinical routine and clinical tri-66 
als.5 Therefore, there is a growing need to identify new, inexpensive and scalable biomarkers in 67 
medical oncology. 68 
While comprehensive molecular and genetic tests are hard to implement at scale, tissue sections 69 
stained with hematoxylin and eosin (H&E) are ubiquitously available. We hypothesized that these 70 
routine tissue sections contain information about established and candidate biomarkers and that 71 
molecular biomarkers could be inferred directly from digitized whole slide images (WSI). The ra-72 
tionale for this hypothesis is that genetic changes in tumor cells cause functional changes, which 73 
can influence tumor cell morphology.6,7 In addition to such first-order genotype-phenotype cor-74 
relations, genetic changes in tumor cells can influence the tumor microenvironment, resulting in  75 
higher-order genotype-phenotype correlations. Specific examples for such correlations are 76 
known for microsatellite instability (MSI)8, a clinically approved biomarker for cancer immuno-77 
therapy in colorectal cancer.9 In the case of MSI, the genotype-phenotype correlation is con-78 
sistent enough to robustly infer the genotype just by observing morphological features in a his-79 
tological image, as we have previously shown.10 Other previous studies have identified genotype-80 
phenotype links for selected genetic features in lung cancer11,12, prostate cancer13, head and 81 




investigated the presence of genotype-phenotype links for a wide range of clinically relevant mo-83 
lecular features across all major solid tumor types. Specifically, we asked which molecular fea-84 
tures leave a strong enough footprint in histomorphology so they can be inferred from histology 85 
images alone with deep learning. We aimed to use deep learning in a pan-molecular pan-cancer 86 
approach, with a focus on clinically relevant genetic molecular features. Such an approach could 87 
ultimately yield clinically useful biomarkers with favorable cost, time and material requirements. 88 
More specifically, this approach could guide a more narrow indication for molecular testing, in-89 
creasing the pre-test probability of a given molecular feature. Independently of potential clinical 90 
application, inferring genetic changes from histology images could also elucidate biological mech-91 
anisms of downstream effects of molecular alterations in solid tumors. Therefore, we developed, 92 
optimized and externally validated a new deep learning pipeline to determine molecular features 93 







All experiments were conducted in accordance with the Declaration of Helsinki and the Interna-98 
tional Ethical Guidelines for Biomedical Research Involving Human Subjects. Anonymized 99 
scanned whole slide images were retrieved from The Cancer Genome Atlas (TCGA) project 100 
through the Genomics Data Commons Portal (https://portal.gdc.cancer.gov/). We applied our 101 
method to 14 of the most common solid tumor types: breast (BRCA)16, cervical (CESC)17, colorec-102 
tal (COAD and READ)18, gastric (STAD)19, head and neck (HNSC)20, hepatocellular (LIHC)21, lung 103 
adeno (LUAD)22, lung squamous (LUSC)23, melanoma (SKCM)24, pancreatic (PAAD)25, prostate 104 
(PRAD)26, renal chromophobe (KICH)27, renal clear cell (KIRC)28 and renal papillary cancer (KIRP)29. 105 
Melanoma (SKCM) tissue slides in the TCGA database comprised primary tumor samples as well 106 
as metastasis tissue. These groups were analyzed separately. For external validation, we acquired 107 
colorectal cancer tissue samples from the DACHS study30,31, which were retrieved from the tissue 108 
bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) as described be-109 
fore.10 110 
Molecular	labels	111 
The aim of this study was to predict clinically relevant features, including genetic alterations, di-112 
rectly from routine histology slides. We systematically applied this screening approach to four 113 
groups of molecular alterations: First, we used single-gene mutations, considering any genetic 114 
variant. We used the most commonly mutated genes in the respective tumor types (derived from 115 
the “cbioportal” database32,33 at http://cbioportal.org) and clinically targetable genes (level one 116 
genes from OncoKB at http://www.oncokb.org, Pan Cancer Atlas Project34). We required each 117 
mutation to affect at least four patients in a given cohort. Second, we repeated the analysis on 118 
putative and confirmed oncogenic driver mutations only, as defined in OncoKB. Third, we aimed 119 
to predict gene expression subtypes, relevant gene expression signatures and immune-cell gene 120 
expression signatures derived from systematic studies35-37. Fourth, we used “standard of care” 121 
features derived from the TCGA database (data at http://portal.gdc.cancer.gov), including hor-122 




and standard features) are listed in Suppl. Table 1. For each individual target label in each tumor 124 
type and each cross-validation run, we re-trained a single deep neural network, using identical 125 
hyperparameters. Features with continuous values were binarized at the mean. 126 
Image	preprocessing		127 
Scanned whole slide images of diagnostic tissue slides (formalin-fixed paraffin-embedded tissue) 128 
stained with hematoxylin and eosin were acquired in SVS format. All images were downsampled 129 
to 20x magnification, corresponding to 0.5 µm/pixel (px). Each whole slide image was manually 130 
reviewed and the tumor area with was annotated under direct supervision of a specialty 131 
pathologist. During annotation, all observers were blinded with regard to any molecular or clini-132 
cal feature. Only those images containing at least 1 mm2 contiguous tumor tissue were used for 133 
downstream analysis. 6% of whole slide images, corresponding to 5% of patients were excluded 134 
due to technical artifacts or lack of tumor (Suppl. Table 2). Tumor tissue on all other slides was 135 
tessellated into square tiles of 512x512 px edge length, corresponding to 256x256 µm at a reso-136 
lution of 0.5 µm/px. Tiles with more than 50% background were discarded; background pixels 137 
were defined by brightness over 0.86 (220/255). For the benchmark task (identification of an 138 
optimal neural network model), these images were resized to 224x224 px (at 1.14 µm/ px) to be 139 
consistent with a previous study10. All steps in the data preprocessing pipeline (including prepro-140 
cessing of images and preprocessing of metadata) are documented in detail in our in-house man-141 
ual for data preparation, which is publicly available at https://dx.doi.org/10.5281/ze-142 
nodo.3694994. All methods for whole slide image processing, including tessellation of images 143 
and visualization of spatial activation maps, were implemented in QuPath v0.1.2 in Groovy 144 
(http://qupath.github.io).  145 
Patient-level	cross-validation	146 
Aiming to develop a one-stop-shop method for systematic discovery of genotype-phenotype links 147 
in multiple cancer types, we developed a reusable pipeline of data processing steps. One or more 148 
whole slide images (WSI) per patient were collected tumor regions in these images were tessel-149 
lated into tiles. All tiles inherited the molecular label of their parent patient. Before training, the 150 




partitions. Neural networks were trained on two partitions each and subsequently evaluated on 152 
the third partition. Thus, no tiles from a given patient were ever part of a training set and a test 153 
set for the same classifier. Before training, tile libraries were randomly undersampled in such a 154 
way that the number of tiles per label was identical for each label (Fig. 1a). 155 
Neural	network	training,	model	selection	and	hyperparameter	optimization	156 
Deep neural networks were trained on image tiles with the aim of predicting molecular labels. 157 
All neural networks were pre-trained on the ImageNet database as described previously10 and 158 
were specifically modified for the classification task at hand by replacing the three top layers with 159 
a 1000-neuron fully connected layer, a softmax layer and a classification layer. For training, we 160 
used on-the-fly data augmentation (random horizontal and vertical reflection) to achieve rota-161 
tional invariance of the classifiers. Hyperparameter selection was performed for five commonly 162 
used deep neural networks: resnet18, alexnet, inceptionv3, densenet201 and shufflenet. The 163 
sampled hyperparameter space was as follows: learning rate 5e-5 and 1e-4, maximum number 164 
of tiles per whole slide image: 250, 500 and 750, number of trainable layers: 10, 20 and 30. We 165 
trained for four epochs with a mini batch size of 512, similar to previous experiments.10 As a 166 
benchmark task, we used MSI detection in colorectal cancer as described before.10  167 
Inference	of	molecular	status		168 
During inference, a categorical prediction was made for each tile by the neural network (Fig. 1b). 169 
The percentage of positive predicted tiles for each class was regarded as a “probability score” for 170 
each patient. This score was used as the free variable for a receiver operating characteristic (ROC) 171 
analysis with area under the ROC curve (AUROC) being the primary endpoint for each target fea-172 
ture. AUROC values are reported as mean with a confidence interval representing lower and up-173 
per range of a 10x bootstrapped experiment. To quantify if predictions for different classes of 174 
patients were statistically significant, the probability scores for patients in a given class were 175 
compared to probability scores of all other patients. Statistical significance of these differences 176 
was assessed with a two-tailed t-test with a pre-defined significance level of 0.05. To compensate 177 




(FDR) correction for p-values with the Benjamini-Hochberg method on all p-values across all can-179 
cer types. All p-values smaller than 10-5 after FDR-correction are reported as 10-5. Statistical 180 
methods are further described in Suppl. Fig. 1a-c. The number of tiles generated per whole slide 181 
image is shown in Suppl. Fig. 2. Training and inference were performed on our local computing 182 
cluster on 10 Nvidia RTX graphics processing units (GPUs), each with 24 GB of GPU RAM. Cumu-183 
lative computing time for all experiments within this study was approximately 12,000 GPU-hours. 184 
All deep learning algorithms were implemented in Matlab R2019a (Mathworks, Natick, MA, USA). 185 
External	validation	186 
To investigate if complex deep learning biomarkers generalize to external patient cohorts, we 187 
trained deep learning classifiers on all TCGA samples of a given tumor type and externally vali-188 
dated the predictions in patient cohorts from our respective institutions. External validation was 189 
performed for BRAF mutation status and CpG island methylator phenotype (CIMP) in colorectal 190 
cancer in N=408 patients, a subset of the multicenter DACHS study which was previously col-191 
lected and described.10 BRAF and CIMP were chosen as validation markers because of their bio-192 
logical relevance and availability of robust measurements of these markers in the DACHS cohort.  193 
Feature	visualization	194 
To visualize the deep learning predictions and make them understandable to human observers, 195 
we used two approached: First, we rendered the tile-level soft predictions for each class as acti-196 
vation maps, visualizing prediction scores as a heatmap overlay on the original histology image. 197 
Second, we identified the highest-predicted tiles of the highest-predicted true positive patients 198 
for each class, allowing observers to identify histological patterns that are correlated with a mo-199 
lecular feature. These approaches were designed to allow human observers to identify which 200 
morphological features deep learning classifiers were most sensitive to.  201 
Alternative	approaches	202 
In our baseline approach, image tiles from manually annotated tumor regions on formalin-fixed 203 
paraffin-embedded (FFPE) slides (diagnostic slides) were used. This approach was compared to 204 




normalization of image tiles with the Macenko method38 to mitigate differences in staining in-206 
tensity and hue (Suppl. Fig. 4). Some previous studies have used color normalization for deep 207 
learning10, while other studies have shown that color normalization can bias histology image clas-208 
sification.39 The second alternative approach we investigated was to use tiles from the whole 209 
slide, as opposed to the tumor region only. In this “weakly supervised” approach, many tiles with-210 
out invasive cancer tissue were present in the training and inference sets (Suppl. Fig. 5). The third 211 
alternative approach was to use frozen slides as opposed to FFPE slides in a weakly supervised 212 
way (Suppl. Fig. 6). 213 
Data	availability	214 
All data (including histological images) from the TCGA database are available at https://por-215 
tal.gdc.cancer.gov/. All molecular data for patients in the TCGA cohorts are available at 216 
https://cbioportal.org. Raw data for Figures and Suppl. Figures are shown in Suppl. Table 3. 217 
Code	availability	218 







We hypothesized that deep learning can infer molecular alterations directly from routine histol-223 
ogy images across multiple common solid tumor types. To test this, we developed, optimized and 224 
extensively validated a new ‘one-stop-shop’ workflow to train and evaluate deep learning net-225 
works. To select an efficient network model and to optimize the deep learning hyperparameters, 226 
prediction of microsatellite instability (MSI) in colorectal cancer was used as a clinically relevant 227 
benchmark task10. In this benchmark, we sampled a large hyperparameter space with different 228 
commonly used deep learning models10,11,14,40 which were modified specifically for this applica-229 
tion. Unexpectedly, ‘shufflenet’41, a lightweight neural network architecture performed similarly 230 
to more complex networks including ‘densenet’42, ‘inception’43 and ‘resnet’44 networks, which 231 
are used in many other studies45 (Fig. 1c). Shufflenet demonstrated high accuracy at a low train-232 
ing time (raw data in Suppl. Table 1, N=426 patients in the TCGA cohort). Shufflenet is optimized 233 
for mobile devices, making this deep neural network architecture attractive for decentralized 234 
point-of-care image analyses or direct implementation in microscopes46. We externally validated 235 
the best shufflenet classifier by training on N=426 patients in the TCGA-CRC cohort10 and validat-236 
ing on N=379 patients with available MSI status in the DACHS cohort10, reaching an AUROC of 237 
0.89 [0.88; 0.92].This represents an improvement over the previous best performance of 0.84 in 238 
that dataset10 and supports the notion that shufflenet is an efficient and powerful neural network 239 
model which can infer clinically relevant molecular changes directly from histology images.  240 
Pan-cancer	prediction	of	genetic	variants	from	histology	241 
Having thus identified a deep neural network model and a set of suitable hyperparameters, we 242 
systematically applied this approach to hundreds of molecular alterations in 14 major tumor 243 
types, and trained and evaluated deep learning networks by three-fold cross-validation on each 244 
cohort. This yielded approximately 104 independently trained deep neural networks which were 245 
systematically evaluated and compared across molecular features across cancer types. The full 246 
list of candidate mutations (Suppl. Table 1) included all point mutations targetable by FDA-ap-247 




Fig. 1d). First, we trained deep neural networks to detect any sequence variants in these target 249 
genes. We found that in 13 out of 14 tested tumor types, the mutation of one or more of such 250 
genes could be inferred from histology images alone, with statistical significance after correction 251 
for multiple testing (Fig. 2a-n, Suppl. Fig. 7). In particular, in major cancer types such as lung ad-252 
enocarcinoma, colorectal cancer, breast cancer and gastric cancer, alterations of several genes 253 
of particular clinical and/or biological examples were detectable (Fig. 2a-d). Examples include 254 
mutations in TP53, which could be significantly detected in all four of these cancer types, as well 255 
as mutations of BRAF in colorectal cancer (TCGA-COAD and TCGA-READ18, N=555, Fig. 2b), MTOR 256 
– a candidate for targeted treatment47 – in gastric cancer (Fig. 2d) and FBXW7 mutation in lung 257 
adenocarcinoma (TCGA-LUAD22, N=457, Fig. 2a) and gastric cancer (TCGA-STAD19, N=321, Fig. 258 
2d). Mutations of PIK3CA (which is directly targetable by a small molecule inhibitor48) was signif-259 
icantly detectable in breast cancer (TCGA-BRCA16, N=995, Fig. 2c) and gastric cancer (Fig. 2d). In 260 
addition, in breast cancer, mutations of MAP2K4 (which is a potential biomarker for response to 261 
MEK inhibitors49) were significantly detectable (Fig. 2c). Among all tested tumor types, gastric 262 
cancer (Fig. 2d) and colorectal cancer (Fig. 2b) had the highest absolute number of detectable 263 
mutations. For all statistically significant features, the mean cross-validated area under the re-264 
ceiver operating curve (AUROC) for the top eight mutations ranged from 0.60 to 0.78 in lung 265 
adenocarcinoma (Suppl. Fig. 8); from 0.65 to 0.76 in colorectal cancer (Suppl. Fig. 9); from 0.62 266 
to 0.78 in breast cancer (Suppl. Fig. 10) and from 0.66 to 0.78 in gastric cancer (Suppl. Fig. 11). 267 
Beyond these four tumor types, a range of notable mutations could be detected in other tumor 268 
types: While in melanoma (TCGA-SKCM24) primary tumors, few mutations were detectable 269 
(Suppl. Fig. 12a-h), in melanoma metastases, mutations in FBXW7 and PIK3CA were significantly 270 
detectable (Fig. 2e, Suppl. Fig. 12i-p). In prostate cancer (TCGA-PRAD26, N=397 patients, Fig. 2f, 271 
Suppl. Fig. 13), our method detected TP53 and FOXA1 mutations from histology, among others. 272 
In pancreatic adenocarcinoma (TCGA-PAAD25, N=171 patients, Fig. 2g, Suppl. Fig. 14), identifying 273 
KRAS wild type patients is of high clinical relevance because these patients are potential candi-274 
dates for targeted treatment and our method significantly identified KRAS genotype in pancreatic 275 
cancer. Lung squamous cell carcinoma is known for its difficulty in molecular diagnosis and few 276 




that in this cancer type, tumor histomorphology is not well correlated to mutations and corre-278 
spondingly, few mutations were significantly detectable in this tumor type in our experiments 279 
(TCGA-LUSC, N=413, Fig. 2h, Suppl. Fig. 15). In hepatocellular carcinoma (TCGA-LIHC21, N=358 280 
patients, Fig. 2i), the β-catenin gene (CTNNB1) is a key driver gene with broad prognostic and 281 
predictive implications50 and its mutational status was highly significantly detected from histol-282 
ogy (Suppl. Fig. 16). In papillary (Fig. 2j, Suppl. Fig. 17) and clear cell renal cell carcinoma (Fig. 2k, 283 
Suppl. Fig. 18), alterations in multiple genes including KRAS and PBRM were highly significantly 284 
detectable while in and chromophobe renal cell carcinoma (Fig. 2l, Suppl. Fig. 19), no genetic 285 
variants were significantly detectable, possibly due to a low patient number in this cohort. In 286 
head and neck squamous cell carcinoma (TCGA-HNSC20, N=435 patients), genotype of CASP8, 287 
which is linked to resistance to cell death51, was significantly detected (Fig. 2m, Suppl. Fig. 20). In 288 
cervical cancer (TCGA-CESC17, N=261 patients), mutations in TCERG1, STK11, AMER1, among oth-289 
ers, were significantly detectable with high AUROC values (Fig. 2n, Suppl. Fig. 21). Raw data for 290 
prediction performance in any gene in any tumor type are available in Suppl. Table 3. 291 
Pan-cancer	prediction	of	oncogenic	drivers	from	histology	292 
Not all genetic variants are causative of malignant processes. Therefore, we repeated the screen-293 
ing experiment, limiting mutations to confirmed or putative oncogenic drivers (Fig. 3a-n). With 294 
this criterion, the absolute number of patients affected by a particular mutation was lower and 295 
thus, fewer genes met the threshold of at least four positive cases in a given tumor type. On the 296 
other hand, we hypothesized that oncogenic driver genes could leave a stronger pattern in his-297 
tological morphology due to their higher biological relevance. Genetic variants in classical onco-298 
genes such as TP53 and KRAS are almost always oncogenic drivers and correspondingly, muta-299 
tions of these genes reached similar prediction accuracy valued in the “drivers only” experiment 300 
when compared to the “all variants” approach (Fig. 3a-n). For other genes, prediction accuracy 301 
increased when limited to oncogenic drivers: a notable example was EGFR in lung adenocarci-302 
noma (Fig. 3a). In summary, these data show that deep learning can detect a wide range of tar-303 
getable and potentially targetable point mutations directly from histology across multiple preva-304 





In the next step, we asked if established molecular subtypes and gene expression signatures of 307 
cancer and immune cells could be detected by deep learning. Compared to single-gene muta-308 
tions, these changes occur at a higher functional level and we hypothesized that their morpho-309 
logical impact could be larger than that of single mutations. To address this hypothesis, we chose 310 
features with known biological and potential clinical significance. A major group of such features 311 
are immune-related gene expression signatures37 of CD8-positive lymphocytes, macrophages, 312 
cell proliferation, interferon-gamma (IFNg) signaling and transforming growth factor-beta (TGFb) 313 
signaling (full list available in Suppl. Table 1). These biological processes are involved in response 314 
to cancer treatment, including immunotherapy. Detecting their morphological correlates in his-315 
tology images could facilitate the development of more nuanced treatment strategies. Indeed, 316 
across all investigated tumor types, we saw that these high-level biological features were much 317 
better predictable than genetic variants or driver mutations (Fig. 4a-d and Suppl. Fig. 7) Again, 318 
AUROC values for significantly (p<0.05 after FDR correction) predictable features were highest in 319 
lung adenocarcinoma (Fig. 4e), colorectal cancer (Fig. 4f), breast cancer (Fig. 4g) and gastric can-320 
cer (Fig. 4h). In lung adenocarcinoma, signatures of proliferation, macrophage infiltration and T-321 
lymphocyte infiltration were significantly detectable from images with high AUROCs (Fig. 4e). 322 
Similarly, significant AUROCs for these biomarkers were achieved in colorectal cancer (Fig. 4f) 323 
breast cancer (Fig. 4g) and gastric cancer (Fig. 4h). In gastric cancer, we additionally found that a 324 
signature of stem cell properties (stemness) was highly detectable directly from histology images 325 
(Fig. 4h). Recent studies have clustered tumors into comprehensive ‘molecular subtypes’37. We 326 
found that our method could detect TCGA molecular subtypes37 with up to AUROC 0.74 in lung 327 
adenocarcinoma (Fig. 4e), pan-gastrointestinal subtypes36 with up to AUROC 0.76 in colorectal 328 
cancer (Fig. 4f) and PAM50 subtypes with up to AUROC 0.78 in breast cancer (Fig. 4g), among 329 
other molecular subtypes. These findings could open up new options for clinical trials of cancer: 330 
While accumulating evidence shows that such molecular clusters of tumors reflect biologically 331 
distinct groups and are correlated to clinical outcome, deep molecular classification of these tu-332 
mors is usually not available in clinical routine or clinical trials. Detecting these subtypes merely 333 




broadly available routine material, potentially helping to identify new biomarkers for treatment 335 
response or to guide specific molecular testing.  336 
Prediction	of	standard	histological	biomarkers	with	deep	learning	337 
To comprehensively evaluate the potential clinical use of our new deep learning pipeline, we 338 
investigated classification accuracy for standard histopathological biomarkers. We found that 339 
deep learning could highly significantly predict most of these biomarkers for breast cancer (Fig. 340 
4c and i), gastric cancer (Fig. 4d and j) and other tumor types (Suppl. Fig. 11-18). In particular, 341 
status of hormone receptors was predictable from routine histology in breast cancer, with an 342 
AUROC of 0.82 for estrogen receptor and 0.74 for progesterone receptor (Fig. 4i). Together, these 343 
results demonstrate that deep-learning-based inference of genetic alterations, high-level molec-344 
ular alterations and established biomarkers from routine diagnostic histology slides is feasible.  345 
Evaluation	of	alternative	approaches		346 
Deep learning-based inference of molecular features from histology is a relatively novel field of 347 
research and it can be anticipated that technical improvements can further improve prediction 348 
performance. We quantified the effect of alternative technical approaches in the colorectal can-349 
cer cohort (TCGA-COAD/READ). First, we investigated the role of color normalization of tiles. In a 350 
head-to-head comparison to the baseline approach, we found a tendency of Macenko’s38 color 351 
normalization to improve classifier performance for mutation prediction but not for predition of 352 
subtypes or gene expression signatures (Suppl. Fig. 4a-c). Second, we investigated a weakly su-353 
pervised approach to our baseline of expert-annotated tumor regions and found that the weakly 354 
supervised approach was only slightly inferior to manual annotation (Suppl. Fig. 4d-f). Third, we 355 
analyzed prediction performance on frozen slides compared to diagnostic slides. While frozen 356 
slides are not generally available in a clinical setting, the TCGA database provides an opportunity 357 
to perform such a direct comparison. In a weakly supervised experiment, we found that predic-358 
tion power for driver genes was on par, but prediction power for genetic variants and high-level 359 
subtypes/signatures was better in frozen slides than in diagnostic slides (Suppl. Fig. 4g-h). These 360 





Deep learning approaches to a single dataset are prone to overfit and should be validated in 363 
external populations before clinical deployment. For external validation of our method, we used 364 
routine H&E slides of N=408 colorectal cancer patients from the DACHS study for which BRAF 365 
mutational status and CpG-island methylator phenotype (CIMP) was available. We trained deep 366 
learning classifiers for BRAF and CIMP on TCGA colorectal cancer samples and evaluated the pa-367 
tient-level accuracy on DACHS. Both features were statistically significantly detectable from 368 
DACHS H&E images alone: For BRAF mutants, AUROC was 0.77 (0.64 – 0.82, p<10-5) and for CIMP-369 
high, AUROC was 0.66 [0.56– 0.72, p<10-5). These data show that deep-learning-based prediction 370 







Our results demonstrate the feasibility of pan-cancer deep-learning-based inference of a broad 375 
range of molecular and genetic features directly from histological images. We show that a unified 376 
workflow yields reliably high performance across multiple clinically relevant scenarios without 377 
the need to tune technical parameters to a specific molecular target. Our systematic screening 378 
approach identifies candidate genetic variants, driver genes, gene expression signatures and 379 
standard of care features that can be significantly inferred from histology images, opening up 380 
perspectives for large-scale validation of these candidate markers. As a large-scale, systematic 381 
screening study, this work identifies a number of mutations which are significantly linked to a 382 
detectable phenotype in histological images, including those in key oncogenic pathways including 383 
TP53, FBXW7, KRAS, BRAF and CTNNB1. In addition to individually mutated genes, our data show 384 
that higher-level gene expression clusters or signatures can be inferred from histological images. 385 
Many of these clusters represent groups of patients with distinct and well-described cancer biol-386 
ogy such as consensus molecular subtype (CMS) in colorectal cancer. By linking these molecularly 387 
defined groups to specific histological image features, our method constitutes a new tool to de-388 
cipher downstream biological effects of molecular alterations in solid tumors. In an external val-389 
idation cohort, we show that the models trained on images from the TCGA archive generalize to 390 
external patients, demonstrating the potential of applying these methods to routine material 391 
from real-world clinical cohorts. Of note, additional retrospective and prospective validation and 392 
regulatory approval is needed for histology-based deep learning methods to be implemented in 393 
clinical workflows. An example for clinical implementation would be the use as pre-screening 394 
tools to enrich patient populations for specific molecular testing. While it is expected that the 395 
first applications of deep learning technology in routine workflows will relate to the automatic 396 
identification of tumor tissues for the selection of specimens or regions of interest, our method 397 
could be easily added to such digital pathology workflows, providing a strong additional incentive 398 





Currently, limitations of our method are the low AUROC values for some molecular features (Fig. 401 
2 and Fig. 3). A strategy to increase the diagnostic performance would be re-training on larger 402 
patient cohorts. Re-training can be expected to boost performance because previous studies 403 
have shown that performance of deep learning systems in histopathology scales with the number 404 
of patients in the training cohort.40 In addition, the performance of deep learning systems could 405 
potentially be improved by technical modifications. Our systematic evaluation of alternative 406 
technical approaches provides a guidance for this on multiple levels: First, regarding the choice 407 
of neural network models, our results demonstrate that lightweight neural network models per-408 
form on par with more complex models, facilitating further evaluation of these methods on de-409 
centralized hardware, including desktop or ultimately mobile hardware. While this finding is 410 
based on a clinically relevant benchmark task and generalizes to an external population, we can-411 
not exclude that other network models perform better in other histology applications. Second, 412 
regarding the type of input image data, other studies in digital pathology have used frozen his-413 
tology sections11. In contrast, our baseline workflow was based on FFPE tissue slides (labeled as 414 
‘diagnostic slides’ in the TCGA archive) due to their clinical relevance. In clinical settings, frozen 415 
specimens constitute only a small fraction of pathology samples and therefore, establishing 416 
methods on FFPE material is paramount for large-scale clinical validation. Our head-to head com-417 
parison shows that molecular inference generally works better on frozen slides, which is a limi-418 
tation of the FFPE-based method. Further studies are needed to determine the reasons for this 419 
observation. Lastly, our baseline method relied on expert annotations of tumor tissue, constrain-420 
ing deep learning models to learn from invasive tumor tissue only. The rationale behind this de-421 
sign was that despite advances in computer vision, expert annotation of tumor tissue remains 422 
the gold standard in histopathology studies. Yet, in a head-to-head comparison, a weakly super-423 
vised approach without any manual annotation did not markedly reduce performance, demon-424 
strating feasibility of even simpler data preprocessing pipelines. We publicly release all source 425 





Beyond being a potentially useful tool for clinical applications, deep learning-based inference of 428 
molecular features from morphology could shed light on more fundamental properties of cancer 429 
biology. Our study systematically screens hundreds of molecular alterations and identifies candi-430 
dates that are linked to detectable patterns in histology images. These patterns can be visualized 431 
through prediction maps (Fig. 5a-e). Such “spatialization” of genetic predictions is a key aspect 432 
lacking in conventional bulk genetic tests of tumor and could be useful to trace back molecular 433 
alterations to specific spatial regions. An alternative approach to understanding deep-learning-434 
based predictions is through visualization of highly ranked image tiles (Fig. 5f-k). This approach 435 
can serve as a plausibility control and may help to discover new morphological features. Indeed, 436 
highly ranked tiles of CMS classes in colorectal cancer showed poorly differentiated tumor in 437 
CMS1 tiles (Fig. 5f), well-differentiated glands for CMS2-3 (Fig. 5g-h) and highly stromal tiles for 438 
CMS4 (Fig. 5i). These patterns correspond to known biological processes underlying CMS sub-439 
classes, corroborating the assumption that our deep learning system detects biologically mean-440 
ingful features. Similarly, visualizing histomorphology in the highest predicted tiles in BRAF mu-441 
tant patients in the validation cohort (Fig. 5j-k) demonstrated poorly differentiated areas and 442 
mucinous areas as recurring features in BRAF mutant image tiles, which is consistent with previ-443 
ous studies.52 Visualizing highly predicted tiles in gastric cancer (Suppl. Fig. 22a-h) highlighted 444 
highly cellular areas as correlates of a “Proliferation” gene expression signature, but at the same 445 
time identified patterns for mutations (e.g. in AMER1 and MTOR) which could help to form new 446 
hypotheses on how these specific mutations influence cancer cell behavior and morphology. In-447 
terestingly, the prediction performance markedly varied between the 14 different types of cancer 448 
(Fig. 2, Suppl. Fig. 7). Variations in sample size between the cohorts could explain some of these 449 
differences, but additional biological effects could contribute to this. One hypothesis is that tu-450 
mor types with few clinically targetable mutations (e.g. lung squamous cell cancer and pancreatic 451 
cancer) also display few detectable mutations. Further studies are warranted to investigate this. 452 
Conclusion	453 
Together, our results demonstrate that molecular changes in solid tumors can be inferred from 454 




genotype-phenotype relationships in cancer and ultimately, could be used as a low-cost bi-456 
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Fig. 1: Deep learning workflow for prediction of molecular features from histology images. We 484 
describe a comprehensive method pipeline for prediction of molecular features directly from his-485 
tological images. (a) Training of the deep learning system comprised six steps. Step 1: Patient 486 
cohorts were randomly split into three partitions for cross-validation of deep classifiers. Step 2: 487 
The tumor region on each whole slide image (WSI) was tessellated into tiles. Step 3: Up to 500 488 
randomly chosen tiles were collected. Step 4: Tiles from patients in the training partitions were 489 
collected, classes were equalized by random undersampling. Step 5: All training tiles were used 490 
to train a deep neural network (pre-trained on a non-medical task). Step 6: Classification perfor-491 
mance was evaluated on patients from the test partition. (b) For patient-level inference of mo-492 
lecular labels in patients not seen during training, three successive steps were used. Step 1: Tiles 493 
were generated from the tumor region on WSI. Step 2: A prediction was made for each tile. Step 494 
3: Tile-level class predictions were pooled on a patient level. (c) Hyperparameters of the deep 495 
learning system were optimized in a benchmark task (prediction of microsatellite instability sta-496 
tus [MSI] in colorectal cancer). The opacity of each point corresponds to the number of trainable 497 
layers (Suppl. Table 3). Shufflenet, a lightweight neural network architecture was selected as a 498 
highly efficient network model. (d) This workflow was subsequently applied for prediction of four 499 
types of molecular features across 14 cancer types. In particular, this included genetic mutations. 500 
The distribution of the 20 most common among all analyzed mutations is shown for each tumor 501 
type.  502 
Fig. 2: Inference of genetic mutations from histological images. A deep learning system was 503 
trained to predict mutational status (mutated or wild-type) of relevant genes in 14 cancer type 504 
and was evaluated by cross-validation. All mutations, including variants of unknown significance, 505 
were included in the ‘mutated’ class. For each gene, patient-level test set performance is shown 506 
as area under the receiver operating curve (AUROC) with p-value for prediction scores corrected 507 
for multiple testing (false detection rate, FDR). The significance level of 0.05 is marked with a line 508 
and the distribution of p-values in each panel is shown as a density plot. P values smaller than 10-509 




colorectal cancer, breast cancer and gastric cancer, a number of relevant genes were significantly 511 
predictable from histology alone, including key oncogenic drivers such as TP53, BRAF and MTOR. 512 
(e-n) In all other tested tumor types, mutational status was predictable for some genes, with 513 
notable examples including KRAS in pancreatic cancer, CTNNB1 in hepatocellular carcinoma and 514 
TP53 and CASP8 in head and neck cancer.  515 
Fig. 3: Inference of putative oncogenic drivers from histological images. A deep learning system 516 
was trained to predict oncogenic driver genes from histology. Only putative and confirmed driv-517 
ers were included and variants of unknown significance were pooled with the “wild type” class. 518 
(a-n) This process uncovered significant predictability of multiple oncogenic drivers, including 519 
EGFR, BRAF and TP53.  520 
Fig. 4: Inference of molecular subtypes, gene expression signatures and standard biomarkers di-521 
rectly from histology. In addition to prediction of single-gene mutations, the capability of deep 522 
learning to infer high-level molecular features was systematically assessed. (a-d) In lung, colorec-523 
tal, breast and gastric cancer, gene expression signatures (such as TCGA molecular subtype in any 524 
tumor type) and standard of care features (such as hormone receptor status in breast cancer) 525 
were highly predictable from histology alone, as shown by the distribution of false-detection rate 526 
(FDR)-corrected p-values. (e-h) Gene expression signatures for Proliferation (Prolif), Wound Heal-527 
ing (WoundHeal), Macrophage infiltration (Mcrphg), Homologous Repair Deficiency (HRD), CD8-528 
positive Lymphocyte (LymCD8), TCGA molecular subtypes (LUAD 1-6), pan-gastrointestinal (GI) 529 
molecular subtypes, consensus molecular subtypes (CMS), PAM50 subtypes and other key mo-530 
lecular features were highly predictable across multiple tumor types. Patient-level AUROC with 531 
bootstrapped confidence intervals, * denotes FDR-p-value < 0.05. (i-j) Standard of care bi-532 
omarkers including estrogen and progesterone receptor (ER and PR) status in breast cancer, path-533 
ologic subtype and microsatellite instability (MSI) were highly predictable from routine histology 534 
alone by deep learning.  535 
Fig. 5: Explainability of deep learning-based analysis of histological images. Deep learning-based 536 
predictions were visualized through genotype maps and comparison of highly ranked image tiles. 537 




resolved prediction scores, unveiling intratumor heterogeneity of predicted genotype. As a ge-539 
neric tool, this visualization approach allows to identify spatial regions associated with a molec-540 
ular feature. In this patient, the correct prediction of CMS4 correctly show that deep learning 541 
robustly predicts CMS from histology alone while highlighting potential intratumor heterogeneity 542 
(f-i) For each of the CMS classes, the most highly scored test set tiles are shown, enabling corre-543 
lation of deep learning-predictions with histopathological features at high resolution. In this case, 544 
highly predicted CMS1 tiles contain numerous tumor-infiltrating lymphocytes while predicted 545 
CMS4 tiles contain abundant stroma, consistent with previous studies. (j-k) Highly scored tiles in 546 
the external test cohort DACHS for prediction of BRAF mutant and wild type (l-m) and CpG-island 547 
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Suppl. Fig. 1: Additional details on the statistical procedures. (a) For patient-level three-fold 668 
cross-validation, the patient cohort was split into three random partitions. Each partition had 669 
approximately the same proportion of patients within each class. Three classifiers were trained 670 
and their patient-level predictions on the respective test set were concatenated. Thus, a predic-671 
tion was gained for each patient in the cohort, but no patient was ever part of a training set and 672 
a test set of the same classifier at the same time. (b) The percentage of predicted tiles for each 673 
class was used for a receiver operating characteristic (ROC) analysis with 10x bootstrapped 674 
pointwise confidence bounds. (c) In addition to the ROC analysis, the prediction scores (percent 675 
predicted tiles) for patients in each class was compared to prediction scores for patients in all 676 
other classes. The resulting false-detection-rate (FDR)-corrected p-value in a two-tailed t-test for 677 
this comparison was reported for each feature of interest. Icons are from Twitter Twemoji (CC-678 
BY 4.0 license). 679 
Suppl. Fig. 2: Distribution of tumor content across slides in all tumor types. Central mark = me-680 
dian, bottom and top edge of the box = 25th and 75th percentile, line extends to the most extreme 681 
data points, circles = outliers. Outliers larger than 2000 mm2 are not plotted. Median tumor con-682 
tent on slide is 139 mm2 of tumor tissue per slide for colorectal cancer (CRC).  683 
Suppl. Fig. 3: Design of additional technical optimization experiments. The baseline approach in 684 
this study was to perform image analysis of tiles based on manual tumor annotations in every 685 
single tissue slide, without performing any color normalization. This approach was compared to 686 
three alternative approaches as shown here. 687 
Suppl. Fig. 4: Results of additional technical optimization experiments: Normalization. (a) Com-688 
parison of cross-validated absolute differences in AUROC to the baseline model (no normaliza-689 
tion), genetic variants. (b) Comparison of AUROC differences for genetic driver mutations. (c) 690 




Suppl. Fig. 5: Results of additional technical optimization experiments: Weakly supervised. (a) 692 
Comparison of cross-validated absolute differences in AUROC to the baseline model (no normal-693 
ization), genetic variants. (b) Comparison of AUROC differences for genetic driver mutations. (c) 694 
Comparison of AUROC differences for expression signatures and subtypes. 695 
Suppl. Fig. 6: Results of additional technical optimization experiments: Frozen tissue. (a) Com-696 
parison of cross-validated absolute differences in AUROC to the baseline model (no normaliza-697 
tion), genetic variants. (b) Comparison of AUROC differences for genetic driver mutations. (c) 698 
Comparison of AUROC differences for expression signatures and subtypes. 699 
Suppl. Fig. 7: Distribution of predictability scores for feature classes in all cancer types. Target 700 
features were assigned to one of four categories as shown in Suppl. Table 1: Genetic variants, 701 
oncogenic drivers, high-level signatures and standard-of-care features. For each of these classes, 702 
predictability by deep learning was assessed and the distribution of false-detection-rate (FDR)-703 
corrected p-values is shown, with low p-values capped at 10-5. High-level signatures were highly 704 
predictable in most tumor types.  705 
Suppl. Fig. 8: Detailed prediction statistics for lung adenocarcinoma (LUAD). (a-c) Area under the 706 
receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 707 
view of the features with highest AUROC values. Low p-values capped at 10-5.  708 
Suppl. Fig. 9: Detailed prediction statistics for colorectal cancer (COAD, READ). (a-c) Area under 709 
the receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) De-710 
tailed view of the features with highest AUROC values. Low p-values capped at 10-5.  711 
Suppl. Fig. 10: Detailed prediction statistics for breast cancer (BRCA). (a-c) Area under the re-712 
ceiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 713 
view of the features with highest AUROC values. Low p-values capped at 10-5.  714 
Suppl. Fig. 11: Detailed prediction statistics for gastric cancer (STAD). (a-c) Area under the re-715 
ceiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 716 




Suppl. Fig. 12: Detailed prediction statistics for melanoma (SKCM) primary tumors and metasta-718 
ses. (a-c) Area under the receiver operating curve (AUROC) with corresponding p-values, for each 719 
feature, for primary tumors. (e-h) Detailed view of the features with highest AUROC values. Low 720 
p-values capped at 10-5, for primary tumors. (i-l)   721 
Suppl. Fig. 13: Detailed prediction statistics for prostate cancer (PRAD). (a-c) Area under the re-722 
ceiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 723 
view of the features with highest AUROC values. Low p-values capped at 10-5.  724 
Suppl. Fig. 14: Detailed prediction statistics for pancreatic cancer (PAAD). (a-c) Area under the 725 
receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 726 
view of the features with highest AUROC values. Low p-values capped at 10-5.  727 
Suppl. Fig. 15: Detailed prediction statistics for lung squamous cell carcinoma (LUSC). (a-c) Area 728 
under the receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) 729 
Detailed view of the features with highest AUROC values. Low p-values capped at 10-5.  730 
Suppl. Fig. 16: Detailed prediction statistics for hepatocellular carcinoma (LIHC). (a-c) Area under 731 
the receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) De-732 
tailed view of the features with highest AUROC values. Low p-values capped at 10-5.  733 
Suppl. Fig. 17: Detailed prediction statistics for renal papillary cancer (KIRP). (a-c) Area under the 734 
receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 735 
view of the features with highest AUROC values. Low p-values capped at 10-5.  736 
Suppl. Fig. 18: Detailed prediction statistics for renal clear cell cancer (KIRC). (a-c) Area under the 737 
receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 738 
view of the features with highest AUROC values. Low p-values capped at 10-5.  739 
Suppl. Fig. 19: Detailed prediction statistics for renal chromophobe cancer (KICH). (a-c) Area un-740 
der the receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) 741 




Suppl. Fig. 20: Detailed prediction statistics for head and neck cancer (HNSC). (a-c) Area under 743 
the receiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) De-744 
tailed view of the features with highest AUROC values. Low p-values capped at 10-5.  745 
Suppl. Fig. 21: Detailed prediction statistics for cervical cancer (CESC). (a-c) Area under the re-746 
ceiver operating curve (AUROC) with corresponding p-values, for each feature. (e-h) Detailed 747 
view of the features with highest AUROC values. Low p-values capped at 10-5.  748 
Suppl. Fig. 22: Highest scoring tiles for molecular features in gastric cancer (STAD). (a-b) Top tiles 749 
corresponding to AMER1 mutational status. (c-d) Top tiles corresponding to MTOR mutational 750 
status. (e-f) Top tiles corresponding to high or low values of a proliferation signature. (a-b) Top 751 
tiles corresponding to hypermutated samples.  752 





Suppl. Table 1: All investigated molecular labels. 755 
Suppl. Table 2: Slide numbers and case numbers for each cohort (diagnostic slides, TCGA). For 756 
melanoma (TCGA-SKCM), the total number of patients included in the analysis was N=430, of 757 
which N=290 had a tissue slide of the primary tumor available and N=141 had a tissue slide of 758 
metastatic tissue available. 759 
Suppl. Table 3: All raw values for prediction experiments, alternative methods and hyperparam-760 
eter optimization experiments. 761 





